Comparing the Cost Effectiveness of Risperidone and Olanzapine in the Treatment of Schizophrenia Using the Net-Benefit Regression Approach

Author： >   >  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.27, Iss.1, 2009-01, pp. : 69-80

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effectiveness and Cost of Risperidone and Olanzapine for Schizophrenia: A Systematic Review

By Hargreaves William A.  

CNS Drugs, Vol. 19, Iss. 5, 2005-01 ,pp. : 393-410

Adis International

Access to resources Recommend Favorite

Cost Analysis of the Treatment of Schizophrenia in the UK: A Simulation Model Comparing Olanzapine, Risperidone and Haloperidol

By Almond S.  

PharmacoEconomics, Vol. 17, Iss. 4, 2000-04 ,pp. : 383-389

Adis International

Access to resources Recommend Favorite

Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies

By Zethraeus N.  

PharmacoEconomics, Vol. 21, Iss. 1, 2003-01 ,pp. : 39-48

Adis International

Access to resources Recommend Favorite

Cost-Benefit Analysis of Risperidone and Clozapine in the Treatment of Schizophrenia in Israel

By Ginsberg G.  

PharmacoEconomics, Vol. 13, Iss. 2, 1998-02 ,pp. : 231-241

Adis International

Access to resources Recommend Favorite

Olanzapine and risperidone on a par in schizophrenia

By  

Inpharma, Vol. 1, Iss. 1240, 2000-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite